Dendrimer-based nanocarriers: a versatile platform for drug delivery

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 9, Issue 1, 2017, Pages

  Hsu, Hao Jui ^a   Bugno, Jason ^a   Lee, Seung Ri ^a   Hong, Seungpyo ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCK COPOLYMERS; DENDRIMERS; GENE THERAPY; NANOSTRUCTURED MATERIALS;

CARRYING CAPABILITY; CLINICAL APPLICATION; CLINICAL TRANSLATION; MULTI-FUNCTIONALIZATION; SYNTHETIC STRATEGIES; SYSTEMIC TOXICITIES; THERAPEUTIC DELIVERY; WELL-DEFINED STRUCTURES;

FUNCTIONAL POLYMERS;

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DENDRIMER; LINEAR DENDRITIC BLOCK COPOLYMER; NANOCARRIER; POLY(PROPYLENIMINE); POLYAMIDOAMINE; POLYLYSINE; POLYMER; UNCLASSIFIED DRUG; VACCINE; NANOPARTICLE;

CONJUGATE; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; GENE TARGETING; MACROMOLECULE; MALIGNANT NEOPLASM; NANOENCAPSULATION; NONHUMAN; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; REVIEW; SOLUBILIZATION; SURFACE CHARGE; TRANSDERMAL DRUG ADMINISTRATION; VACCINATION; NANOTECHNOLOGY;

DENDRIMERS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 85006355367     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1409     Document Type: Review

References (172)

1. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015, 33:941–951.
2. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013, 65:21–23.
3. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412–2417.
4. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794–7803.
5. Ko A, Tempero M, Shan Y, Su W, Lin Y, Dito E, Ong A, Wang Y, Yeh C, Chen L. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013, 109:920–925.
6. Awada A, Bondarenko I, Bonneterre J, Nowara E, Ferrero J, Bakshi A, Wilke C, Piccart M, CT4002 Study Group. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 2014, 25:824–831.
7. Lee CC, MacKay JA, Fréchet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517–1526.
8. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 2005, 57:2106–2129.
9. Hawker CJ, Frechet JM. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 1990, 112:7638–7647.
10. Pearson RM, Sunoqrot S, H-j H, Bae JW, Hong S. Dendritic nanoparticles: the next generation of nanocarriers? Ther Deliv 2012, 3:941–959.
11. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. A new class of polymers: starburst-dendritic macromolecules. Polym J 1985, 17:117–132.
12. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2012, 64:302–315.
13. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR, Holl MMB. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007, 14:107–115.
14. Myung JH, Gajjar KA, Saric J, Eddington DT, Hong S. Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells. Angew Chem Int Ed 2011, 123:11973–11976.
15. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014, 39:268–307.
16. Wu L-P, Ficker M, Christensen JB, Trohopoulos PN, Moghimi SM. Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem 2015, 26:1198–1211.
17. Bugno J, Hsu H-J, Hong S. Recent advances in targeted drug delivery approaches using dendritic polymers. Biomater Sci 2014, 3:1025–1034.
18. Bugno J, Hsu H-J, Hong S. Tweaking dendrimers and dendritic nanoparticles for controlled nano-bio interactions: potential nanocarriers for improved cancer targeting. J Drug Target 2015, 23:642–650.
19. Buhleier E, Wehner W, Vögtle F. "Cascade"-and" nonskid-chain-like" syntheses of molecular cavity topologies. Synthesis 1978, 1978:155–158.
20. Kannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med 2014, 276:579–617.
21. Caminade A-M, Laurent R, Delavaux-Nicot B, Majoral J-P. “Janus” dendrimers: syntheses and properties. New J Chem 2012, 36:217–226.
22. Caminade A-M, Turrin C-O. Dendrimers for drug delivery. J Mater Chem B 2014, 2:4055–4066.
23. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000, 65:133–148.
24. Hong S, Leroueil PR, Janus EK, Peters JL, Kober M-M, Islam MT, Orr BG, Baker JR, Banaszak Holl MM. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem 2006, 17:728–734.
25. Yang Y, Pearson RM, Lee O, Lee CW, Chatterton RT, Khan SA, Hong S. Dendron-based micelles for topical delivery of Endoxifen: a potential chemo-preventive medicine for breast cancer. Adv Funct Mater 2014, 24:2442–2449.
26. Yang Y, Sunoqrot S, Stowell C, Ji J, Lee C-W, Kim JW, Khan SA, Hong S. Effect of size, surface charge, and hydrophobicity of poly (amidoamine) dendrimers on their skin penetration. Biomacromolecules 2012, 13:2154–2162.
27. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, Balogh L, Orr BG, Baker JR, Banaszak Holl MM. Interaction of poly (amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem 2004, 15:774–782.
28. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JM, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 2002, 13:453–461.
29. Pearson RM, H-j H, Bugno J, Hong S. Understanding nano-bio interactions to improve nanocarriers for drug delivery. MRS Bull 2014, 39:227–237.
30. Modi DA, Sunoqrot S, Bugno J, Lantvit DD, Hong S, Burdette JE. Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells. Nanoscale 2014, 6:2812–2820.
31. Sunoqrot S, Bae JW, Pearson RM, Shyu K, Liu Y, Kim D-H, Hong S. Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. Biomacromolecules 2012, 13:1223–1230.
32. Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK. Ligand based dendritic systems for tumor targeting. Int J Pharm 2008, 350:3–13.
33. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65:5317–5324.
34. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri A, Thomas T, Mulé J, Baker J Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002, 19:1310–1316.
35. Myung JH, Gajjar KA, Chen J, Molokie RE, Hong S. Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies. Anal Chem 2014, 86:6088–6094.
36. Myung JH, Launiere CA, Eddington DT, Hong S. Enhanced tumor cell isolation by a biomimetic combination of E-selectin and anti-EpCAM: implications for the effective separation of circulating tumor cells (CTCs). Langmuir 2010, 26:8589–8596.
37. van Dongen MA, Silpe JE, Dougherty CA, Kanduluru AK, Choi SK, Orr BG, Low PS, Banaszak Holl MM. Avidity mechanism of dendrimer–folic acid conjugates. Mol Pharm 2014, 11:1696–1706.
38. Leroueil PR, DiMaggio S, Leistra AN, Blanchette CD, Orme C, Sinniah K, Orr BG, Banaszak Holl MM. Characterization of folic acid and poly(amidoamine) dendrimer interactions with folate binding orotein: a force-pulling study. J Phys Chem B 2015, 119:11506–11512.
39. Wurm F, Frey H. Linear–dendritic block copolymers: the state of the art and exciting perspectives. Prog Polym Sci 2011, 36:1–52.
40. Esfand R, Tomalia DA. Poly (amidoamine)(PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001, 6:427–436.
41. Labieniec-Watala M, Watala C. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. J Pharm Sci 2015, 104:2–14.
42. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10:35–43.
43. Boas U, Christensen JB, Heegaard PM. Dendrimers: design, synthesis and chemical properties. J Mater Chem 2006, 16:3785–3798.
44. Shao N, Su Y, Hu J, Zhang J, Zhang H, Cheng Y. Comparison of generation 3 polyamidoamine dendrimer and generation 4 polypropylenimine dendrimer on drug loading, complex structure, release behavior, and cytotoxicity. Int J Nanomed 2011, 6:3361–3372.
45. Richter-Egger DL, Tesfai A, Tucker SA. Spectroscopic investigations of poly (propyleneimine) dendrimers using the solvatochromic probe phenol blue and comparisons to poly (amidoamine) dendrimers. Anal Chem 2001, 73:5743–5751.
46. Kannaiyan D, Imae T. pH-dependent encapsulation of pyrene in PPI-core: PAMAM-shell dendrimers. Langmuir 2009, 25:5282–5285.
47. Denkewalter R, Kole J, Lukasavage W. Macromolecular highly branched homogeneous compound based on lysine units. US Patent 4289872, 1981.
48. Falkovich S, Markelov D, Neelov I, Darinskii A. Are structural properties of dendrimers sensitive to the symmetry of branching? Computer simulation of lysine dendrimers. J Chem Phys 2013, 139:064903.
49. Gillies ER, Dy E, Fréchet JM, Szoka FC. Biological evaluation of polyester dendrimer: poly (ethylene oxide)“bow-tie” hybrids with tunable molecular weight and architecture. Mol Pharm 2005, 2:129–138.
50. Gillies ER, Fréchet JM. Designing macromolecules for therapeutic applications: polyester dendrimer poly (ethylene oxide)“bow-tie” hybrids with tunable molecular weight and architecture. J Am Chem Soc 2002, 124:14137–14146.
51. Zhang S, Sun H-J, Hughes AD, Moussodia R-O, Bertin A, Chen Y, Pochan DJ, Heiney PA, Klein ML, Percec V. Self-assembly of amphiphilic Janus dendrimers into uniform onion-like dendrimersomes with predictable size and number of bilayers. Proc Natl Acad Sci USA 2014, 111:9058–9063.
52. Gitsov I, Wooley KL, Frechet JM. Novel polyether copolymers consisting of linear and dendritic blocks. Angew Chem Int Ed Engl 1992, 31:1200–1202.
53. Rosen BM, Wilson CJ, Wilson DA, Peterca M, Imam MR, Percec V. Dendron-mediated self-assembly, disassembly, and self-organization of complex systems. Chem Rev 2009, 109:6275–6540.
54. Bae JW, Pearson RM, Patra N, Sunoqrot S, Vukovic L, Kral P, Hong S. Dendron-mediated self-assembly of highly PEGylated block copolymers: a modular nanocarrier platform. Chem Commun 2011, 47:10302–10304.
55. Yang B, Sun Y-X, Yi W-J, Yang J, Liu C-W, Cheng H, Feng J, Zhang X-Z, Zhuo R-X. A linear-dendritic cationic vector for efficient DNA grasp and delivery. Acta Biomater 2012, 8:2121–2132.
56. Medina SH, El-Sayed ME. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009, 109:3141–3157.
57. Naylor AM, Goddard WA, Kiefer GE, Tomalia DA. Starburst dendrimers. 5. Molecular shape control. J Am Chem Soc 1989, 111:2339–2341.
58. Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, Finkelstein S, Lee SJ, Grinstaff MW. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003, 125:15485–15489.
59. Patri AK, Kukowska-Latallo JF, Baker JR Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005, 57:2203–2214.
60. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 2000, 11:910–917.
61. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10:767–776.
62. Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 2006, 5:52–59.
63. Kono K, Kojima C, Hayashi N, Nishisaka E, Kiura K, Watarai S, Harada A. Preparation and cytotoxic activity of poly (ethylene glycol)-modified poly (amidoamine) dendrimers bearing adriamycin. Biomaterials 2008, 29:1664–1675.
64. Li X, Takashima M, Yuba E, Harada A, Kono K. PEGylated PAMAM dendrimer–doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. Biomaterials 2014, 35:6576–6584.
65. Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 2013, 441:701–711.
66. Nance E, Porambo M, Zhang F, Mishra MK, Buelow M, Getzenberg R, Johnston M, Kannan RM, Fatemi A, Kannan S. Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury. J Control Release 2015, 214:112–120.
67. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, Romero R, Kannan RM. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 2012, 4:130ra146.
68. Zhang C, Pan D, Luo K, She W, Guo C, Yang Y, Gu Z. Peptide dendrimer–doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Adv Healthcare Mater 2014, 3:1299–1308.
69. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002, 6:466–471.
70. Nguyen PM, Hammond PT. Amphiphilic linear-dendritic triblock copolymers composed of poly (amidoamine) and poly (propylene oxide) and their micellar-phase and encapsulation properties. Langmuir 2006, 22:7825–7832.
71. Yang Y, Hua C, Dong C-M. Synthesis, self-assembly, and in vitro doxorubicin release behavior of dendron-like/linear/dendron-like poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε-caprolactone) triblock copolymers. Biomacromolecules 2009, 10:2310–2318.
72. H-j H, Sen S, Pearson RM, Uddin S, Král P, Hong S. Poly (ethylene glycol) corona chain length controls end-group-dependent cell interactions of dendron micelles. Macromolecules 2014, 47:6911–6918.
73. Percec V, Wilson DA, Leowanawat P, Wilson CJ, Hughes AD, Kaucher MS, Hammer DA, Levine DH, Kim AJ, Bates FS. Self-assembly of Janus dendrimers into uniform dendrimersomes and other complex architectures. Science 2010, 328:1009–1014.
74. She W, Luo K, Zhang C, Wang G, Geng Y, Li L, He B, Gu Z. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron–doxorubicin conjugates for cancer therapy. Biomaterials 2013, 34:1613–1623.
75. Li N, Li N, Yi Q, Luo K, Guo C, Pan D, Gu Z. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 2014, 35:9529–9545.
76. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751–760.
77. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387–6392.
78. Wu W, Driessen W, Jiang X. Oligo (ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. J Am Chem Soc 2014, 136:3145–3155.
79. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Konishi J, Togashi K, Brechbiel MW. Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J Magn Reson Imaging 2001, 14:705–713.
80. Agarwal A, Gupta U, Asthana A, Jain NK. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials 2009, 30:3588–3596.
81. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, Porter CJ. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm 2009, 6:1190–1204.
82. http://www.starpharma.com/drug_delivery/dep_docetaxel. (Accessed January 11, 2016).
83. Zhu J, Shi X. Dendrimer-based nanodevices for targeted drug delivery applications. J Mater Chem B 2013, 1:4199–4211.
84. Zhang Y, Thomas TP, Lee K-H, Li M, Zong H, Desai AM, Kotlyar A, Huang B, Banaszak Holl MM, Baker J JR. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer–methotrexate conjugate as a potential anticancer agent. Bioorg Med Chem 2011, 19:2557–2564.
85. He H, Li Y, Jia X-R, Du J, Ying X, Lu W-L, Lou J-N, Wei Y. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 32:478–487.
86. Thomas TP, Patri AK, Myc A, Myaing MT, Ye JY, Norris TB, Baker JR. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 2004, 5:2269–2274.
87. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, Kotlyar A, Baker JR. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006, 17:1109–1115.
88. Wang Y, Guo R, Cao X, Shen M, Shi X. Encapsulation of 2-methoxyestradiol within multifunctional poly (amidoamine) dendrimers for targeted cancer therapy. Biomaterials 2011, 32:3322–3329.
89. Fu F, Wu Y, Zhu J, Wen S, Shen M, Shi X. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. ACS Appl Mater Interfaces 2014, 6:16416–16425.
90. Zhu J, Fu F, Xiong Z, Shen M, Shi X. Dendrimer-entrapped gold nanoparticles modified with RGD peptide and α-tocopheryl succinate enable targeted theranostics of cancer cells. Colloids Surf B 2015, 133:36–42.
91. Wang K, Zhang X, Zhang L, Qian L, Liu C, Zheng J, Jiang Y. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release. Drug Deliv 2015, 22:389–399.
92. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011, 32:1242–1252.
93. Somani S, Blatchford DR, Millington O, Stevenson ML, Dufès C. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J Control Release 2014, 188:78–86.
94. Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials 2014, 35:5539–5548.
95. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly (propylene imine) dendrimers: a comparison. Nanomedicine 2011, 7:295–304.
96. Sideratou Z, Kontoyianni C, Drossopoulou GI, Paleos CM. Synthesis of a folate functionalized PEGylated poly (propylene imine) dendrimer as prospective targeted drug delivery system. Bioorg Med Chem Lett 2010, 20:6513–6517.
97. Singh Dhakad R, Kumar Tekade R, Kumar Jain N. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr Drug Deliv 2013, 10:477–491.
98. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013, 19:6193–6204.
99. Jain K, Gupta U, Jain NK. Dendronized nanoconjugates of lysine and folate for treatment of cancer. Eur J Pharm Biopharm 2014, 87:500–509.
100. Zhu J, Xiong Z, Shen M, Shi X. Encapsulation of doxorubicin within multifunctional gadolinium-loaded dendrimer nanocomplexes for targeted theranostics of cancer cells. RSC Adv 2015, 5:30286–30296.
101. Zhu J, Zheng L, Wen S, Tang Y, Shen M, Zhang G, Shi X. Targeted cancer theranostics using α-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials 2014, 35:7635–7646.
102. Sunoqrot S, Bae JW, Jin S-E, Pearson RM, Liu Y, Hong S. Kinetically controlled cellular interactions of polymer−polymer and polymer−liposome nanohybrid systems. Bioconjug Chem 2011, 22:466–474.
103. Sunoqrot S, Bugno J, Lantvit D, Burdette JE, Hong S. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release 2014, 191:115–122.
104. Sunoqrot S, Liu Y, Kim D-H, Hong S. In vitro evaluation of dendrimer–polymer hybrid nanoparticles on their controlled cellular targeting kinetics. Mol Pharm 2012, 10:2157–2166.
105. Sun Q, Sun X, Ma X, Zhou Z, Jin E, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ, Lott JR. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv Mater 2014, 26:7615–7621.
106. Bugno J, Hsu H-J, Pearson RM, Tam KA, Hong S. Size and surface charge of engineered poly(amidoamine) dendrimers modulate tumor accumulation and penetration: a model study using multicellular tumor spheroids. Mol Pharm 2016, doi:10.1021/acs.molpharmaceut.5b00946.
107. Mishra MK, Kotta K, Hali M, Wykes S, Gerard HC, Hudson AP, Whittum-Hudson JA, Kannan RM. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 2011, 7:935–944.
108. Gajbhiye V, Ganesh N, Barve J, Jain NK. Synthesis, characterization and targeting potential of Zidovudine loaded sialic acid conjugated-mannosylated poly (propyleneimine) dendrimers. Eur J Pharm Sci 2013, 48:668–679.
109. Choi SK, Myc A, Silpe JE, Sumit M, Wong PT, McCarthy K, Desai AM, Thomas TP, Kotlyar A, Holl MMB. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano 2012, 7:214–228.
110. Lazniewska J, Milowska K, Gabryelak T. Dendrimers—revolutionary drugs for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4:469–491.
111. Sun B, Slomberg DL, Chudasama SL, Lu Y, Schoenfisch MH. Nitric oxide-releasing dendrimers as antibacterial agents. Biomacromolecules 2012, 13:3343–3354.
112. Lu Y, Slomberg DL, Shah A, Schoenfisch MH. Nitric oxide-releasing amphiphilic poly(amidoamine) (PAMAM) dendrimers as antibacterial agents. Biomacromolecules 2013, 14:3589–3598.
113. Worley BV, Slomberg DL, Schoenfisch MH. Nitric oxide-releasing quaternary ammonium-modified poly(amidoamine) dendrimers as dual action antibacterial agents. Bioconjug Chem 2014, 25:918–927.
114. Landers JJ, Cao Z, Lee I, Piehler LT, Myc PP, Myc A, Hamouda T, Galecki AT, Baker JR. Prevention of influenza pneumonitis by sialic acid–conjugated dendritic polymers. J Infect Dis 2002, 186:1222–1230.
115. García-Gallego S, Díaz L, Jiménez JL, Gómez R, de la Mata FJ, Muñoz-Fernández MÁ. HIV-1 antiviral behavior of anionic PPI metallo-dendrimers with EDA core. Eur J Med Chem 2015, 98:139–148.
116. Rupp R, Rosenthal SL, Stanberry LR. VivaGel™(SPL7013 Gel): A candidate dendrimer–microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007, 2:561–566.
117. Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res 2011, 90:195–199.
118. Chen W, Turro NJ, Tomalia DA. Using ethidium bromide to probe the interactions between DNA and dendrimers. Langmuir 2000, 16:15–19.
119. Zhou J, Wu J, Hafdi N, Behr J-P, Erbacher P, Peng L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006:2362–2364.
120. Kabanov V, Sergeyev V, Pyshkina O, Zinchenko A, Zezin A, Joosten J, Brackman J, Yoshikawa K. Interpolyelectrolyte complexes formed by DNA and astramol poly (propylene imine) dendrimers. Macromolecules 2000, 33:9587–9593.
121. Haensler J, Szoka FC Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993, 4:372–379.
122. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002, 19:960–967.
123. Tang MX, Redemann CT, Szoka FC. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996, 7:703–714.
124. Posocco P, Liu X, Laurini E, Marson D, Chen C, Liu C, Fermeglia M, Rocchi P, Pricl S, Peng L. Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing. Mol Pharm 2013, 10:3262–3273.
125. Karatasos K, Posocco P, Laurini E, Pricl S. Poly (amidoamine)-based dendrimer/siRNA complexation studied by computer simulations: effects of pH and generation on dendrimer structure and siRNA Binding. Macromol Biosci 2012, 12:225–240.
126. Reyes-Reveles J, Sedaghat-Herati R, Gilley DR, Schaeffer AM, Ghosh KC, Greene TD, Gann HE, Dowler WA, Kramer S, Dean JM. mPEG-PAMAM-G4 nucleic acid nanocomplexes: enhanced stability, RNase protection, and activity of splice switching oligomer and poly I: C RNA. Biomacromolecules 2013, 14:4108–4115.
127. Sun Y, Jiao Y, Wang Y, Lu D, Yang W. The strategy to improve gene transfection efficiency and biocompatibility of hyperbranched PAMAM with the cooperation of PEGylated hyperbranched PAMAM. Int J Pharm 2014, 465:112–119.
128. Arima H, Kihara F, Hirayama F, Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjug Chem 2001, 12:476–484.
129. Anno T, Higashi T, Motoyama K, Hirayama F, Uekama K, Arima H. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate. Int J Pharm 2012, 426:239–247.
130. Wang M, Liu H, Li L, Cheng Y. A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios. Nat Commun 2014, 5:3053.
131. Liu H, Wang Y, Wang M, Xiao J, Cheng Y. Fluorinated poly(propylenimine) dendrimers as gene vectors. Biomaterials 2014, 35:5407–5413.
132. Wang M, Cheng Y. The effect of fluorination on the transfection efficacy of surface-engineered dendrimers. Biomaterials 2014, 35:6603–6613.
133. Wood KC, Little SR, Langer R, Hammond PT. A family of hierarchically self-assembling linear-dendritic hybrid polymers for highly efficient targeted gene delivery. Angew Chem Int Ed 2005, 44:6704–6708.
134. Liu X, Zhou J, Yu T, Chen C, Cheng Q, Sengupta K, Huang Y, Li H, Liu C, Wang Y. Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems. Angew Chem Int Ed 2014, 53:11822–11827.
135. Yu T, Liu X, Bolcato-Bellemin AL, Wang Y, Liu C, Erbacher P, Qu F, Rocchi P, Behr JP, Peng L. An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo. Angew Chem Int Ed 2012, 51:8478–8484.
136. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85:5409–5413.
137. Tam JP. Recent advances in multiple antigen peptides. J Immunol Methods 1996, 196:17–32.
138. Defoort J-P, Nardelli B, Huang W, Ho DD, Tam JP. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc Natl Acad Sci USA 1992, 89:3879–3883.
139. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:1–8.
140. Moreno CA, Rodriguez R, Oliveira GA, Ferreira V, Nussenzweig RS, Castro ZRM, Calvo-Calle JM, Nardin E. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine 1999, 18:89–99.
141. Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, Hall BF, Diggs C, Bodison S, Edelman R. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 2000, 182:1486–1496.
142. Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schneider M, Tiercy J-M, Loutan L, Hochstrasser D, Rose K. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001, 166:481–489.
143. Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C, Nardin EH. A linear peptide containing minimal T-and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun 2006, 74:6929–6939.
144. Heegaard PM, Boas U, Sorensen NS. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem 2009, 21:405–418.
145. Schuster T, Nussbaumer M, Baumann P, Bruns N, Meier W, Car A. Polymeric particulates for subunit vaccine delivery. In: Foged C, Rades T, Perrie Y, Hook S, eds. Subunit Vaccine Delivery. New York: Springer; 2015, 181–201.
146. Niederhafner P, Reiniš M, Šebestík J, Ježek J. Glycopeptide dendrimers, part III—a review: use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J Pept Sci 2008, 14:556–587.
147. Lo-Man R, Vichier-Guerre S, Bay S, Dériaud E, Cantacuzène D, Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol 2001, 166:2849–2854.
148. Ponchel G, Irache J-M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998, 34:191–219.
149. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004, 95:447–453.
150. Najlah M, Freeman S, Attwood D, D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 2007, 336:183–190.
151. Goldberg DS, Vijayalakshmi N, Swaan PW, Ghandehari H. G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J Control Release 2011, 150:318–325.
152. Liu Y, Chiu GNC. Dual-functionalized PAMAM dendrimers with improved P-glycoprotein inhibition and tight junction modulating effect. Biomacromolecules 2013, 14:4226–4235.
153. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 2003, 20:1543–1550.
154. Sadekar S, Thiagarajan G, Bartlett K, Hubbard D, Ray A, McGill L, Ghandehari H. Poly (amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int J Pharm 2013, 456:175–185.
155. Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, Diwan PV. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003, 90:335–343.
156. Yiyun C, Na M, Tongwen X, Rongqiang F, Xueyuan W, Xiaomin W, Longping W. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 2007, 96:595–602.
157. Venuganti VVK, Perumal OP. Effect of poly (amidoamine)(PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int J Pharm 2008, 361:230–238.
158. Venuganti VVK, Perumal OP. Poly (amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration. J Pharm Sci 2009, 98:2345–2356.
159. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005, 57:2215–2237.
160. Jain K, Kesharwani P, Gupta U, Jain N. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010, 394:122–142.
161. Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 2007, 8:3853–3859.
162. Chen H-T, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc 2004, 126:10044–10048.
163. Hong S, Rattan R, Majoros IJ, Mullen DG, Peters JL, Shi X, Bielinska AU, Blanco L, Orr BG, Baker JR Jr. The role of ganglioside GM1 in cellular internalization mechanisms of poly (amidoamine) dendrimers. Bioconjug Chem 2009, 20:1503–1513.
164. Pearson RM, Patra N, Hsu H-J, Uddin S, Král P, Hong S. Positively charged dendron micelles display negligible cellular interactions. ACS Macro Lett 2012, 2:77–81.
165. Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, Porter CJ. Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. Mol Pharm 2007, 4:949–961.
166. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93–102.
167. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 2010, 383:293–296.
168. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm 2008, 5:449–463.
169. Wong C-H, Zimmerman SC. Orthogonality in organic, polymer, and supramolecular chemistry: from Merrifield to click chemistry. Chem Commun 2013, 49:1679–1695.
170. Zeng F, Zimmerman SC. Rapid synthesis of dendrimers by an orthogonal coupling strategy. J Am Chem Soc 1996, 118:5326–5327.
171. Kolb HC, Finn M, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed 2001, 40:2004–2021.
172. Wu P, Feldman AK, Nugent AK, Hawker CJ, Scheel A, Voit B, Pyun J, Frechet JM, Sharpless KB, Fokin VV. Efficiency and fidelity in a click-chemistry route to triazole dendrimers by the copper (I)-catalyzed ligation of azides and alkynes. Angew Chem Int Ed 2004, 43:3928–3932.